Answers are grounded in this paper and cite their sources.
Retrospective cohort study compares pathological features and kidney prognosis in bucillamine and primary membranous nephropathy, indicating significant differences in histology and clinical outcomes.
To evaluate the pathological and clinical course differences between bucillamine‑induced membranous nephropathy (BCL-MN) and primary membranous nephropathy (p-MN). This retrospective cohort study included 29 BCL-MN patients and 98 p-MN patients at two hospitals from 2000 to 2019. We compared the kidney biopsy findings and clinical course between the BCL-MN and p-MN groups, focusing on pathological differences, proteinuria relapse rates, and 30% or greater decrease in the eGFR. While kidney function and proteinuria levels were similar, histopathological differences were observed. BCL-MN group showed less spike formation in LM and more stage I cases. IgG1 was predominant in BCL-MN group, contrasting with IgG4 in p-MN group. BCL-MN group had significantly higher prevalence of segmental subepithelial deposits (66.7% vs. 24.7%, p < 0.001) and para-mesangial deposits (61.5% vs. 18.1%, p < 0.001). Notably, foot process effacement in areas without dense deposits was more common in BCL-MN (96.3% vs. 4.6%, p < 0.001). Clinically, the majority of patients in the BCL-MN group experienced proteinuria resolution after 1 year of drug discontinuation alone, and there was no progression of renal function decline. BCL-MN differs from p-MN both histologically and clinically, which may be related to the mechanism induced by BCL.
No takes yet. Share an insight, caveat, or question.
Sawa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: